P53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 304-318

  Kobayashi, Takahiko ^a,b   Ishida, Junich ^b   Musashi, Manabu ^a   Ota, Shuichi ^b   Yoshida, Takeshi ^b   Shimizu, Yuichi ^b   Chuma, Makoto ^b   Kawakami, Hiroshi ^b   Asaka, Masahiro ^b   Tanaka, Junji ^b   Imamura, Masahiro ^b   Kobayashi, Masanobu ^c   Itoh, Hiroshi ^d   Edamatsu, Hironori ^e   Sutherland, Leslie C ^f   Brachmann, Rainer K ^g  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^d NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f SUDBURY REGIONAL HOSPITAL   (Canada)

^g GENENTECH INC   (United States)

Author keywords

p53; RBM5; RNA binding protein; transactivation; tumor suppressor gene

Indexed keywords

DNA; DOXORUBICIN; LUCIFERASE; MESSENGER RNA; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; RNA BINDING MOTIF PROTEIN 5; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FEMALE; GENE ISOLATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DNA-BINDING PROTEINS; HUMANS; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 78049415251     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25345     Document Type: Article

References (52)

1. Drabkin HA, West JD, Hotfilder M, Heng YM, Erickson P, Calvo R, Dalmau J, Gemmill RM, Sablitzky F,. DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. Oncogene 1999; 18: 2589-97.
2. Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM, Sekido Y, Lee CC, Geil L, Kuzmin I, Zabarovsky E, Klein G, et al. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 1996; 56: 1487-92.
3. Timmer T, Terpstra P, van den Berg A, Veldhuis PM, Ter Elst A, Voutsinas G, Hulsbeek MM, Draaijers TG, Looman MW, Kok K, Naylor SL, Buys CH,. A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. Eur J Hum Genet 1999; 7: 478-86.
4. Oh JJ, Grosshans DR, Wong SG, Slamon DJ,. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999; 27: 4008-17.
5. Zabarovsky ER, Lerman MI, Minna JD,. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21: 6915-35.
6. Lerman MI, Minna JD,. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60: 6116-33.
7. Maarabouni MM, Williams GT,. The antiapoptotic RBM5/LUCA-15/H37 gene and its role in apoptosis and human cancer: research update. Scientific World J 2006; 6: 1705-12.
8. Sutherland LC, Rintala-Maki ND, White RD, Morin CD,. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J Cell Biochem 2005; 94: 5-24.
9. Oh JJ, West AR, Fishbein MC, Slamon DJ,. A candidate tumor suppressor gene. H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res 2002; 62: 3207-13.
10. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS,. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002; 23: 736-48.
11. Edamatsu H, Kaziro Y, Itoh H,. LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed Rat-1 cells. Genes Cells 2000; 5: 849-58.
12. Mourtada-Maarabouni M, Sutherland LC, Meredith JM, Williams GT,. Simultaneous acceleration of the cell cycle and suppression of apoptosis by splice variant delta-6 of the candidate tumour suppressor LUCA-15/RBM5. Genes Cells 2003; 8: 109-19.
13. Ramaswamy S, Ross KN, Lander ES, Golub TR,. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
14. Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, Slamon DJ,. 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res 2006; 66: 3419-27.
15. Rintala-Maki ND, Sutherland LC,. LUCA-15/RBM5, a putative tumour suppressor, enhances multiple receptor-initiated death signals. Apoptosis 2004; 9: 475-84.
16. Rintala-Maki ND, Abrasonis V, Burd M, Sutherland LC,. Genetic instability of RBM5/LUCA-15/H37 in MCF-7 breast carcinoma sublines may affect susceptibility to apoptosis. Cell Biochem Funct 2004; 22: 307-13.
17. Sutherland LC, Lerman M, Williams GT, Miller BA,. LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells. Oncogene 2001; 20: 2713-19.
18. Mourtada-Maarabouni M, Sutherland LC, Williams GT,. Candidate tumour suppressor LUCA-15 can regulate multiple apoptotic pathways. Apoptosis 2002; 7: 421-32.
19. Mourtada-Maarabouni M, Keen J, Clark J, Cooper CS, Williams GT,. Candidate tumor suppressor LUCA-15/RBM5/H37 modulates expression of apoptosis and cell cycle genes. Exp Cell Res 2006; 312: 1745-52.
20. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-10.
21. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
22. Riley T, Sontag E, Chen P, Levine A,. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-12.
23. Murray-Zmijewski F, Slee EA, Lu X,. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008; 9: 702-12.
24. Toledo F, Wahl GM,. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-23.
25. Bode AM, Dong Z,. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
26. Carter S, Vousden KH,. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19: 18-24.
27. Kobayashi T, Wang T, Qian H, Brachmann RK,. Genetic strategies in S. cerevisiae to study human tumor suppressor genes. In:, El-Deiry WS, ed. Methods in molecular biology, vol. 223: tumor suppressor genes: regulation, function, and medicinal applicationsed. Totowa, NJ: Humana Press, 2003. 73-86.
28. Brachmann RK,. Exploring and restoring the p53 pathway using the p53 dissociator assay in yeast. In:, Nitiss JL, Heitman J, eds. Yeast as tool in cancer research. New York: Springer, 2007. 211-32.
29. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK,. hADA3 is required for p53 activity. EMBO J 2001; 20: 6404-13.
30. Kobayashi T, Wang T, Maezawa M, Kobayashi M, Ohnishi S, Hatanaka K, Hige S, Shimizu Y, Kato M, Asaka M, Tanaka J, Imamura M, et al. Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation. Cancer Res 2006; 66: 3137-44.
31. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M,. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995; 23: 2584-92.
32. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N,. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-8.
33. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B,. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
34. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B,. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-15.
35. Morgenstern JP, Land H,. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-96.
36. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M,. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 2003; 100: 8354-9.
37. Harris SL, Levine AJ,. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-908.
38. Keene JD,. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet 2007; 8: 533-43.
39. Pietsch EC, Sykes SM, McMahon SB, Murphy ME,. The p53 family and programmed cell death. Oncogene 2008; 27: 6507-21.
40. Braithwaite AW, Del Sal G, Lu X,. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ 2006; 13: 984-93.
41. Chen YI, Moore RE, Ge HY, Young MK, Lee TD, Stevens SW,. Proteomic analysis of in vivo-assembled pre-mRNA splicing complexes expands the catalog of participating factors. Nucleic Acids Res 2007; 35: 3928-44.
42. Behzadnia N, Golas MM, Hartmuth K, Sander B, Kastner B, Deckert J, Dube P, Will CL, Urlaub H, Stark H, Luhrmann R,. Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. EMBO J 2007; 26: 1737-48.
43. Wahl MC, Will CL, Luhrmann R,. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136: 701-18.
44. Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY,. Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor. RBM5. Proc Natl Acad Sci USA 2008; 105: 15708-13.
45. Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J,. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 2008; 32: 81-95.
46. Bourdon JC,. p53 and its isoforms in cancer. Br J Cancer 2007; 97: 277-82.
47. Moore MJ, Proudfoot NJ,. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 2009; 136: 688-700.
48. Halaby MJ, Yang DQ,. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 2007; 395: 1-7.
49. Takagi M, Absalon MJ, McLure KG, Kastan MB,. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005; 123: 49-63.
50. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W,. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 1995; 14: 4442-9.
51. Vazquez A, Bond EE, Levine AJ, Bond GL,. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-87.
52. Bassett EA, Wang W, Rastinejad F, El-Deiry WS,. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008; 14: 6376-86.